A pipeline for your therapeutic monoclonal needs.
Our team is building a stream-lined therapeutic humanized-antibody development pipeline that industries can leverage to increase their targets. Our comprehensive approach includes peptide design, ScFv screening, in-vitro evolution, CDR grafting, epitope mapping, antibody sequencing, and determination of post-translational modifications, with every aspect of development custom-tailored to meet your specific requirements. We utilize rigorous in-vitro and in-vivo bio-functional testing to ensure the antibodies we create are highly effective in targeting your desired biological activity.
* Defined epitopes ->
Your target molecule is extensively analyzed to define epitopes that matter using computational methods, including homology modeling, intrinsically disordered domains, solvent accessible area, and variant-specific differences.
* Immunization ->
We use peptide and recombinant protein immunization protocols in parallel. Hybridomas will be generated; monoclonals will be screened on peptide and protein ELISAs. ScFv libraries are generated and screened on target peptides and proteins. Monoclonals & ScFvs are sequenced.
* In-vitro evolution ->
Monoclonlas and ScFvs with suboptimal binding constants (Kd) are modified using in-vitro evolution techniques. We will use iterative screening for high-affinity variants. We will achieve this promptly.
* Humanization ->
The ScFv obtained in our in-vitro evolution will be stitched on the human IgG background ( Isotypes of your choice). We conduct molecular modeling for proper control of the boundaries. The resulting antibodies are cloned and expressed in CHO, Yeast expression backgrounds.
* Function studies ->
We will conduct custom-tailored functional studies. From viral neutralization to cancer cell targetting, we have expertise in establishing in-vitro assays to assess the abilities of these humanized antibodies. We will conduct pharmacokinetic studies and required in-vivo functional studies in small animals.
* Epitopes & PTM
We will map epitopes using overlapping peptide libraries and peptide-display libraries. Peptides will be sequenced using LC-MS/MS or NGS. We will also assess N-, and O- linked glycosylation status and types of glycans, less frequent phosphorylation, and methylation (PTMs) of final antibodies using HDC/ETD LC-MS/MS
Your data is yours!
We understand that confidentiality and ethical standards are paramount when it comes to conducting research and development projects. At our organization, we operate with a strict policy of confidentiality, ensuring that all data and materials related to your project remain completely secure and confidential. This includes cell lines, proteins, sequence information, and all other materials or data associated with your project. We will always prioritize the protection of your intellectual property, and we will be legally bound never to use your antibody information for any other internal or external projects. You can trust us to maintain the highest standards of confidentiality and ethical conduct throughout the entire development process.
Discover about the monoclonals we are developing!
We initiated the development of a set of high-value therapeutic antibodies. To learn more, contact us!
